This is a poetic suicide note

---

Yes - on its own it’s regular cash management by Treasury and would happen regardless/not cause for concern. This routine is to prevent spikes in repo rates/money markets stressing out. But Fed also officially stopped QT at start of the month. Now all treasuries/MBS will mature and principal reinvested. Buying more bonds and putting liquidity in system. Fed balance sheet doesn’t shrink but remains flat and sets up for QE should the market sneeze. Adding liquidity not ideal when currency devaluing, economy not looking certain, Fed talking about cuts. Note - I am biased and hate the Fed/current Treasury pumping money into system.

---

Thinking of writing a YOLO post : don't know if it qualifies. Sold options worth notional risk of around $540,000 and profited around $18,000 within two days. all trades closed. Decent return but does not sound as flashy as these long option plays posted here. what am i going to write? "risked half a million to make 18,000?" Note: this is a regular play for me. The purpose of making a YOLO post is to somehow get a fucking flair that has eluded me till date. Nothing else.

---

Trading drunk is infinitely better than doing it sober. Drunk me apparently loves LEAPS. Side note, taking losses is better drunk as well.

---

LOL thetafuck day TWO. Made a couple grand selling far otm 0DTEs on QQQ and SPY. Notional risk be damned. Spreads are for bitches. ... on a related note, I still have no flair. thought I would point that out. As I wrote before, I have stopped begging for a flair because someone here said it does not work. I bet MODS are sitting on a pile of flairs that are worth nothing to them, yet they won't spare me even ONE of them godamnit fuck

---

But on a serious note, please talk to someone if you're feeling hopeless.

---

former biotech consultant and current clinical trial coordinator and have to agree with you on all of this. it also seems to me that these nucleic acid antitumor therapies work best as a combo regimen and not a standalone. currently bsAbs/tsAbs seem to be getting the most love in terms of actual usage, with CAR-Ts being a "nice to have" for the toolkit but investors are wary of those now haha. i don't see any world where MRNA's therapies achieve 1L or even 2L access, and only as part of a combo regimen with something like keytruda. with the patent cliff approaching, though, i could see bigger biopharma looking to snatch up anything "new" and may enter licensing agreements with MRNA especially if combo regimens are approved. in that case, though, i'd rather just invest in pfizer, merck, and the like. as a side note, also have heard awful things about MRNA work culture; though of course layoffs are crazy high across all biopharma these days. let me know if i'm off anywhere- you seem like you probably know more than me since i haven't kept up with business trends as tightly as when i was really in the game

---

Note to self: when u feel like buying puts, full port calls… duma$$$

---

Take note: BAD news is good news for the markets

---

So I work in the oncology biotech industry. I have written clinical trial protocols and support access of oncology products from both a USA and international perspective. While your thesis is flawed in many numerous ways, I will say the easiest one to call out is that you are way too early. These adjuvant trials take a very long time to finish. My competitive intelligence department clocks INTERpath-009 reading out in mid 2033, which honestly with DFS as an endpoint, will probably take longer. Also note this is in partnership with Merck (who my company has partnered with multiple times), and there is probably some form of revenue split for the product. Merck is probably only supplying free pembro for the trials, which has been their modus operandi in the space with smaller partners. MRNA currently has a cash burn of around $5B a year on a revenue of about $2B. They have about $7B cash on hand. They will need to do multiple capital raises (e.g. probably dilute stock) in order to just stay afloat. As an aside, I have multiple colleagues that work at MRNA and they all say it's one of the most awful places they've ever worked at. Turnover is high and idiocy at the upper management levels is rampant. Honestly, they are all surprised that the company has survived this long given the mishandling of the COVID bag.

---